A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients
Authors:
- Praphan PhanuphakPPPraphan Phanuphak
- Sasiwimol UbolyamSUSasiwimol Ubolyam
- Jongkol SankoteJSJongkol Sankote
- Patcharee PongprayoonPPPatcharee Pongprayoon
- Sukontha SaenawatSSSukontha Saenawat
- Saijai WicharukSWSaijai Wicharuk
- Siriporn NonenoySNSiriporn Nonenoy
- Natnipa WannachaiNWNatnipa Wannachai
- Sineenart ChautrakarnSCSineenart Chautrakarn
- Theshinee ChuenyamTCTheshinee Chuenyam
- Nittaya JeanpanNJNittaya Jeanpan
- Thantip NuchapongTNThantip Nuchapong
- 1 August 2005
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 10 (6) , 761-767
Abstract
Objective: To assess the efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs), as induction therapy before enrollment in a randomized trial of structured treatment interruption strategies. Design: Two-hundred antiretroviral-naive patients with CD4 + cell counts between 200–350 at screening were enrolled in this open-label 24week study. Methods: Patients were followed up every 8 weeks for CD4 + cells, HIV RNA, and clinical and laboratory toxicities. Results: Two-hundred patients were enrolled with median baseline CD4 + cell count of 267 cells/μl and HIV RNA 50 118 (4.7 log 10 ) copies/ml. After 24 weeks of treatment, 191 of 200 (96%) patients had below 400 copies/ml HIV RNA, with 177/200 (89%) below 50 copies/ml (intent to treat, missing equals failure method), with a median rise in CD4 + cell count of 122 cells/μl. There was no significant correlation between the minimum concentration of saquinavir and HIV RNA reductions at week 8 ( P=0.957) or absolute HIV RNA at week 24 ( P=0.77). Conclusion: First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-dailyJournal of Antimicrobial Chemotherapy, 2004
- Treatment for Adult HIV InfectionJAMA, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- SOLOAIDS, 2004
- Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2004
- Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 TrialThe Journal of Infectious Diseases, 2003
- Modelling the 3‐year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) studyHIV Medicine, 2003
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study2002
- Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive PatientsClinical Pharmacokinetics, 1999